Shock therapy: testosterone plus olaparib takes on resistant prostate cancer

NCT ID NCT03516812

Completed Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a combination of testosterone and olaparib in 36 men with castration-resistant prostate cancer. The idea is that testosterone can cause DNA damage in cancer cells that have adapted to low testosterone, while olaparib blocks the cells' ability to repair that damage. The study measured how many men had a significant drop in PSA levels and tracked side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: testosterone and olaparib
What this could lead to: If it works, this could offer a new treatment option for men with prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is a small, early-phase trial with only 36 participants. The combination may cause side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT PROSTATE CARCINOMA PROSTATE ADENOCARCINOMA

Contacts and locations

Locations

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.